Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
-5.16%
+2.20%
+0.32%
+0.85%
-0.40%
SNY
Sanofi
$50.88
Login to see Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid Strengths
Earnings are forecast to grow
Trading below its fair value
Technical Indicators
5+ Days Up
Chart
$46.8 (+8.72%)
$48.61 (+4.67%)
$49.96 (+1.84%)
$54.86 (-7.25%)
SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Investors losing confidence
SNY overall standing based on key factors, offering insights into analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Earnings decline YoY
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
SNY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SNY Street view is extremely bullish and have positive views on the near-term outlook
Average key support and resistance price levels.
Login to displaySNY Earnings
The TTM reflects 12-month period, providing review of SNY financial performance.
The company financial health has shown minor improvement, but significant issues remain
Financial Score
PFE
27.56
+1.75%
NVS
132.77
+1.37%
LLY
844.96
+3.07%
MRK
89.77
+0.27%
ABBV
234.73
-0.80%
What is SNY current stock price?
What are SNY stock strengths?
What risks are associated with SNY stock?
When is SNY next earnings report?
What is SNY market cap and volume?
What is SNY's current Stock IQ?
Should I buy SNY stock right now?
Is SNY a Strong Buy right now?
What does a 'Strong Buy' rating mean for SNY?
What does a 'Strong Sell' rating mean for SNY?
What factors influence SNY's Stock IQ?
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
-5.16%
+2.20%
+0.32%
+0.85%
-0.40%
SNY
Sanofi
Current Price
$50.88
Stock Insights
Strengths
Earnings are forecast to grow
Trading below its fair value
Technical Indicators
5+ Days Up
Linked to SNY
PFE
27.56
+1.75%
NVS
132.77
+1.37%
LLY
844.96
+3.07%
MRK
89.77
+0.27%
ABBV
234.73
-0.80%
Login to unlock Sanofi (SNY) Stock IQ rating and get instant clarity on whether to Buy, Hold, or Avoid
Chart
$46.8 (+8.72%)
$48.61 (+4.67%)
$49.96 (+1.84%)
$54.86 (-7.25%)
SNY Analysts Opinion
SNY Overall standing by considering key factors, reflecting analysts perspectives and market expectations.
Hover over the category for more information
Earnings
Earnings
Earnings decline YoY
Rating
Rating
Momentum
Momentum
Price value has negative momentum
Activity
Activity
Future
Future
Earnings are forecast to grow
Trading below its fair value
SNY Analysts opinion is positive and also has improved from the past 3 months
Analysts perspectives on the stock desirability, trend direction, and growth potential.
SNY Street view is extremely bullish and have positive views on the near-term outlook
SNY has Low Risk Level based on volatility, sector strength, volume, investor confidence, and outlook. Click here to check what is your level of risk
Risks Indicators
Investors losing confidence
Average key support and resistance price levels.
Login to displaySNY Earnings
The TTM data reflects the most recent 12-month period, providing overview of SNY financial performance.
SNY Financial Health
The company financial health has shown minor improvement, but significant issues remain
Financial Score
SNY Latest Analysis
ish Two Hundred Day Moving Average Cross - SNY. In trading on Friday shares of Sanofi (Symbol: SNY) crossed above their 200 day moving average of $50.89 changing hands as high as $51.05 per share. Sanofi shares are currently trading up about 1.7% on the day. The chart below shows the one year performance of SNY shares ve
Today
Novavax Expands Collaboration And License Agreement With Sanofi On Use Of Matrix-M Adjuvant . (RTTNews) - Novavax Inc. (NVAX) announced Tuesday progress on its collaboration and license agreement (CLA) with Sanofi SA (SNY) regarding Novavaxs Matrix-M adjuvant. The companies have amended their CLA to expand Sanofis license to include use of Novavaxs Matrix-M adjuvant i
Tue Sep 30, 2025
Bank of America Securities Maintains Buy on Sanofi (SNY). Sanofi (NASDAQ:SNY) is one of the Ridiculously Cheap Stocks to Buy According to Analysts. On September 22 Bank of America Securities analyst Sachin Jain maintained a Buy rating on Sanofi (NASDAQ:SNY) with a price target of €115. Jain highlighted the companys pipeline as one of the key reasons behind the positive rating. He noted that [….]
Mon Sep 29, 2025
Sanofi Expands Insulin Savings Program To Cover All US Patients. The United States Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for ) SNY is demonstrating ish strength. Caprelsa will remain available with the same prescribing information but health care providers will no longer need special certification or extra monitoring .A REMS is a safety program that the FDA can require for certain medications with serious safety concerns to help ensure
Fri Sep 26, 2025
Sanofi Expands $35 Insulin Program To All United States Patients . (RTTNews) - Sanofi (SNY) on Friday announced a broad expansion of its Insulins Valyou Savings Program under which a 30-day supply of any Sanofi insulin will be available for $35 to all United States patients with a valid prescription.
Fri Sep 26, 2025
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi. ) a clinical-stage oncology company focused on keeping cancer patients alive today announced the pricing of its underwritten public offering of 18959914 shares of its Class A common stock at an offering price of $9.23 per share which is equal to the last reported sale price for Immuneering'.s Class A common stock on
Thu Sep 25, 2025
Immuneering announces public offering $25M private placement with Sanofi. shares up 55%.
Wed Sep 24, 2025
Sanofi Commits $625 Mln To Expand Venture Fund . (RTTNews) - Sanofi Winthrop Industrie SA Sanofi SA (SAN.PA SNY SNYNF) a French pharmaceutical and healthcare company on Wednesday said it has made an additional $625 million multi-year capital commitment to its corporate venture arm Sanofi Ventures.
Wed Sep 24, 2025
Sanofi (SAN:CA) Presents at Bank of America Global Healthcare Conference 2025 Transcript.
Tue Sep 23, 2025
FDA Grants Fast Track Status To Sanofis Gene Therapy For Non-Congenital DM1 . (RTTNews) - The United States Food and Drug Administration has granted Fast Track designation to SAR446268 Sanofis (SNYSNYNFSAN.PA) investigational one-time AAV gene therapy targeting non-congenital forms of myotonic dystrophy type 1 (DM1) including juvenile and adult-onset cases. Th
Tue Sep 23, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Overview
Trending
Screener
Insights
Top Rated
Momentum
Earnings